Merck's melanoma vaccine trial shows reduced recurrence or death from skin cancer

Merck presented its mRNA melanoma vaccine trial data at a European cancer conference this weekend. Results are promising: The vaccine reduces recurrence and death alongside an immunotherapy drug.

Source: NPR Health — Original report ↗

WorldLine News is displaying a source-attributed brief. Details may evolve. The linked publication is responsible for its original reporting.